IL151024A0 - Conjugates of a biopolymer and a therapeutic agent - Google Patents

Conjugates of a biopolymer and a therapeutic agent

Info

Publication number
IL151024A0
IL151024A0 IL15102401A IL15102401A IL151024A0 IL 151024 A0 IL151024 A0 IL 151024A0 IL 15102401 A IL15102401 A IL 15102401A IL 15102401 A IL15102401 A IL 15102401A IL 151024 A0 IL151024 A0 IL 151024A0
Authority
IL
Israel
Prior art keywords
biopolymer
conjugates
therapeutic agent
therapeutic
agent
Prior art date
Application number
IL15102401A
Other languages
English (en)
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of IL151024A0 publication Critical patent/IL151024A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
IL15102401A 2000-02-15 2001-02-15 Conjugates of a biopolymer and a therapeutic agent IL151024A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18255800P 2000-02-15 2000-02-15
US21150800P 2000-06-14 2000-06-14
PCT/US2001/004925 WO2001060412A2 (en) 2000-02-15 2001-02-15 Modification of biopolymers for improved drug delivery

Publications (1)

Publication Number Publication Date
IL151024A0 true IL151024A0 (en) 2003-02-12

Family

ID=26878197

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15102401A IL151024A0 (en) 2000-02-15 2001-02-15 Conjugates of a biopolymer and a therapeutic agent

Country Status (6)

Country Link
EP (1) EP1263472A2 (xx)
JP (1) JP2003522806A (xx)
AU (1) AU2001238346A1 (xx)
CA (1) CA2400205A1 (xx)
IL (1) IL151024A0 (xx)
WO (1) WO2001060412A2 (xx)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040043457A1 (en) * 2001-01-18 2004-03-04 Silke Schumacher Bifunctional fusion proteins with glucocerebrosidase activity
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
WO2004060404A1 (ja) * 2002-12-27 2004-07-22 Chugai Seiyaku Kabushiki Kaisha 薬物担体
US7803386B2 (en) 2003-06-05 2010-09-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Poly-gamma-glutamic conjugates for eliciting immune responses directed against bacilli
CA2529486A1 (en) * 2003-06-18 2004-12-23 Nst Neurosurvival Technologies Ltd. Method for selective targeting of apoptotic cells and small molecule ligands used thereof
US20070092550A1 (en) * 2003-10-10 2007-04-26 Cellular Bioengineering, Inc. Methods and compositions for growing corneal endothelial and related cells on biopolymers and creation of artifical corneal transplants
US7625736B2 (en) 2004-06-04 2009-12-01 The United States Of America As Represented By The Department Of Health And Human Services Methods for preparing immunogenic conjugates
JP5060131B2 (ja) 2004-09-07 2012-10-31 中外製薬株式会社 水溶性ヒアルロン酸修飾物の製造方法
PL1877099T3 (pl) 2005-04-06 2013-02-28 Genzyme Corp Terapeutyczne koniugaty zawierające enzym lizosomalny, kwas polisialowy i grupę kierującą
US20080206276A1 (en) 2005-07-08 2008-08-28 Michael Otto Targeting Poly-Gamma-Glutamic Acid to Treat Staphylococcus Epidermidis and Related Infections
ES2744574T3 (es) 2007-01-18 2020-02-25 Genzyme Corp Oligosacáridos que comprenden un grupo aminooxi y conjugados de los mismos
BR122020010601B8 (pt) 2008-12-16 2021-07-27 Genzyme Corp conjugados de proteína-oligossacarídeo, seus usos, e composições farmacêuticas
SI2682409T1 (sl) 2011-03-03 2017-08-31 Chugai Seiyaku Kabushiki Kaisha Derivat hialuronske kisline modificiran z amino-karboksilno kislino
WO2012140650A2 (en) 2011-04-12 2012-10-18 Hepacore Ltd. Conjugates of carboxy polysaccharides with fibroblast growth factors and variants thereof
EP2894173B1 (en) 2012-09-05 2017-04-19 Chugai Seiyaku Kabushiki Kaisha Hyaluronic acid derivative having amino acid and steryl group introduced thereinto
KR102049568B1 (ko) * 2013-04-01 2019-11-27 삼성전자주식회사 히알루론산을 포함하는 핵산전달용 조성물
GB201602359D0 (en) * 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
CN108440684A (zh) * 2018-03-22 2018-08-24 华侨大学 一种NI-Cys-Alg自组装纳米载体及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0537299A1 (en) * 1990-03-29 1993-04-21 Gilead Sciences, Inc. Oligonucleotide-transport agent disulfide conjugates
US5169934A (en) * 1990-05-14 1992-12-08 Anergen, Inc. Intracellularly cleavable compounds
US6335434B1 (en) * 1998-06-16 2002-01-01 Isis Pharmaceuticals, Inc., Nucleosidic and non-nucleosidic folate conjugates
CA2122717C (en) * 1991-11-08 2003-07-15 David C. Anderson Hemoglobins as drug delivery agents
US5902795A (en) 1992-06-16 1999-05-11 Trustees Of Tufts College Oligosaccharides reactive with hyaluronan-binding protein and their methods of use
US5329029A (en) 1992-11-05 1994-07-12 Wan Barbara Y Phosphatidylalkanolamine derivatives and their use in generating phospholipid conjugates
EP0693924B2 (en) * 1993-02-22 2008-04-09 Abraxis BioScience, Inc. Methods for (in vivo) delivery of biologics and compositions useful therefor
US5354853A (en) 1993-03-12 1994-10-11 Genzyme Corporation Phospholipid-saccharide conjugates
AU734827B2 (en) * 1997-05-21 2001-06-21 Board Of Trustees Of The Leland Stanford Junior University Composition and method for enhancing transport across biological membranes
US5932552A (en) 1997-11-26 1999-08-03 Keraplast Technologies Ltd. Keratin-based hydrogel for biomedical applications and method of production

Also Published As

Publication number Publication date
WO2001060412A3 (en) 2002-01-24
CA2400205A1 (en) 2001-08-23
JP2003522806A (ja) 2003-07-29
AU2001238346A1 (en) 2001-08-27
EP1263472A2 (en) 2002-12-11
WO2001060412A2 (en) 2001-08-23

Similar Documents

Publication Publication Date Title
AU2001285020A1 (en) P97-active agent conjugates and their methods of use
IL151024A0 (en) Conjugates of a biopolymer and a therapeutic agent
PL358335A1 (en) Polyglutamic acid-camptothecin conjugates and methods of preparation
PL354623A1 (en) Manufacture of polyglutamate-therapeutic agent conjugates
EP1367060A4 (en) GLUCOPYRANOSYLOXYBENZYLBENZENE DERIVATIVES AND THEIR MEDICAL USE
EP1364957A4 (en) GLYCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND THEIR MEDICAL USE
EP1364958A4 (en) GLYCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND MEDICINAL USE THEREOF
HK1040995A1 (zh) 二氧喹啉化合物及其醫藥用途
PT1296974E (pt) Derivados 2-cianopirrolidina e sua utilização como medicamentos
AU2001253479A1 (en) Targeted therapeutic agent release devices and methods of making and using the same
IL146842A0 (en) Polymer conjugates of hedgehog proteins and uses
HUP0301076A3 (en) Linezolid-crystal form ii and preparation thereof
HUP0300334A3 (en) Pharmaceutical preparations and their manufacture
GB2377380B (en) Dermatological use and a dermatological preparation
AU2002215300A1 (en) Cancer chemotherapeutical and chemopreventive agent
IL151589A0 (en) New combination of a betablocker and a cholestrol-lowering agent
EP1226154A4 (en) ÖSTRADIOL CONJUGATES AND ITS USE
AU2215302A (en) Therapeutic agent comprising a b-subunit of a protein toxin
HUP0201478A3 (en) Neuroprotective and retinoprotective ophthalmologic medicines
EP1275657A4 (en) PEPTIDE DERIVATIVES AND MEDICINAL COMPOSITIONS
GB0018887D0 (en) Compound and their therapeutic use
HUP0301119A3 (en) Biologically active agent and drug
GB0012718D0 (en) Conjugates of aminodrugs
HUP0302371A3 (en) New pharmaceutical composition comprising a betablocker and optionally a cholesterol-lowering agent
IL153653A0 (en) Novel therapeutic molecular variants and uses thereof